The Board has considered and took on record the Un-audited financial results for the quarter ended June 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Samrat Pharmachem's Board approved its unaudited standalone results for Q1 FY26. Revenue from operations stood at Rs 7,565.16 lakhs, down about 6.4% from Rs 8,082.40 lakhs in the same quarter last year. The company slipped into a loss, reporting a Profit After Tax of Rs (22.89) lakhs versus a profit of Rs 206.55 lakhs in Q1 FY25, with EPS turning negative at Rs (0.74) versus Rs 6.69 a year ago. Profit before tax collapsed to just Rs 20.78 lakhs from Rs 281.85 lakhs, reflecting sharp margin compression despite broadly stable expenses. Sequentially, the business improved slightly from Q4 FY25, when PAT was Rs (39.92) lakhs. The statutory auditor (Shah & Savla LLP) issued an unqualified limited review report with no qualifications or emphasis of matter.
The year-on-year swing from profit to loss and the steep drop in profitability despite only a modest revenue decline signal significant cost pressure and weak operating leverage, which is negative for near-term shareholder sentiment and may weigh on the stock.